Dr. Marc J. Dinkin, MD

Dr. Dinkin practices at Weill Medical College of Cornell University in New York, New York.

Dr. Dinkin's NPI, 1215953740, was assigned on July 15, 2006. Dr. Dinkin graduated from Weill Cornell Medicine in 2002. Dr. Dinkin holds New York license 234177.

Dr. Dinkin's primary practice is Weill Medical College of Cornell University, at 1305 York Ave, New York, NY 10021 in New York County. The practice phone is (646) 962-5483.

Dr. Dinkin's primary practice is Weill Medical College of Cornell University in New York, New York. Dr. Dinkin is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Dinkin to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dinkin practices, 2 sites in all. Vendor and product names are available with a free account.

Neuro-ophthalmology is Dr. Dinkin's primary specialty in the NPI Registry, under taxonomy code 207WX0109X. Dr. Dinkin is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Dinkin's licenses on file in 2 states: New York and Massachusetts.

Dmand AI lists glaucoma, retinal occlusion, vision problems and visual impairment and blindness among the conditions Dr. Dinkin treats.

CMS data shows 1,817 Medicare services from Dr. Dinkin across 10 procedure codes in 2024, for 445 Medicare patients. Medicare paid $121,887 for them. Every service was in an office.

CMS counts 445 Medicare patients who saw Dr. Dinkin in 2024. The largest group is 75 to 84, with 178 patients. 75% of them have high cholesterol, and 63% have high blood pressure. 13% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Dinkin's median patient age at 53, with 57% women.

In 2024, Dr. Dinkin wrote 47 Medicare Part D claims for 30 patients. 94% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $284 in total drug cost. In 2023, CMS named 45 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Dinkin for performance year 2024, reported through an alternative payment model (APM). Dr. Dinkin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dinkin as offering telehealth.

Dmand AI links 77 papers to Dr. Dinkin, published from 2010 to 2025. 2021 was the busiest year, with 7. The most frequent topics are Magnetic Resonance Imaging, COVID-19 and Pseudotumor Cerebri. Dr. Dinkin has published most often in J Neuroophthalmol. Dr. Dinkin's most frequent co-authors are Cristiano Oliveira, MD, Athos Patsalides, MD and Srikanth Reddy Boddu, MD, MS.

Dmand AI links Dr. Dinkin to 2 clinical trials. Conditions studied include Optic Neuropathy, Ischemic, Pseudotumor Cerebri and Intracranial Hypertension.

CMS Open Payments shows 2 general payments to Dr. Dinkin from 2 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $101.

Dmand AI lists 2 awards for Dr. Dinkin, most recently Top Doctors: New York Metro Area in 2014.

Dr. Dinkin graduated from Weill Cornell Medicine in 2002. Dr. Dinkin is a member of AAN.

Dr. Dinkin is in network with 20 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.